By Dr Jean-Luc Vanderheyden As the experience and advances in Positron Emission Tomography (PET) imaging grows, so does the belief that this technology can have a key role to play in ushering in an era of personalised medicine while also offering an enormous contribution in reducing the attrition rates in… Read More
Serial vs Direct Dilution - Time to apply new thinking to IC50 determination and dose-response analysis? By Dr John Comley The serial dilution method is standard practice in the preparation of doseresponse series for IC50 determination. However, it is well recognised that inadequacies in the liquid handling or mixing technique… Read More
By Anthony Rosenberg Partnering and licensing have become paramount in a pharmaceutical industry that is under inordinate pressure to fill pipelines and increase the number of approved new molecular entities. This article discusses how Novartis has gone about addressing this issue. There is a great deal of focus on discovering… Read More
Lean Thinking for Drug Discovery – Better Productivity for Pharma By Dr Edward W. Petrillo Success in drug discovery controls the success of the pharmaceutical enterprise. The molecular structure of every drug candidate, and the body of knowledge that will guide its use in the treatment of disease, are established… Read More
India - Global pharmaceutical R&D powerhouse or contract research workshop? By Dr Matthew Howard In response to the ever-increasing costs of drug discovery and development, pharmaceutical industry leaders must constantly seek to increase productivity while simultaneously reducing costs and maintaining quality. Globalisation of drug discovery may provide such an opportunity,… Read More
Sharing Risks and Rewards - Basis for a turnkey pharma-biotech alliance in osteoarthritis Dr Andre Hoekema In June 2006, Galapagos and GlaxoSmithKline’s Center of Excellence for External Drug Discovery (CEEDD) formed a multi-year worldwide alliance to discover and develop novel drugs for osteoarthritis. The focus of the alliance will be… Read More
Kinase Screening and Profiling Products - Spoilt for choice By Dr John Comley The end user is spoilt for choice with the range of alternative offerings, methodologies and approaches currently available for kinase screening and profiling. Whereas wider coverage of the kinome was the principal focus of kinase profiling a… Read More
Genetics & Personalised Medicine - Whole genome association and genetic linkage studies By Dr John W. Hooper Genetic linkage studies have long been the standard for researching the genetics associated with heritable diseases. Recently, however, scientists have begun to realise the benefits of whole genome association studies, which enable them… Read More
The Role of Microarray Technology in Pharmaceutical Development and Diagnostics By Richard Fisler The expectation that microarray technology will play a large role in shaping the future of pharmaceutical development and diagnostics has greatly increased due to new products and applications. Microarrays for gene expression have made a profound impact… Read More
Emerging concepts of G protein-coupled receptor (GPCR) function and drug discovery By Dr Richard M. Eglen, Dr Roger Bosse and Dr Graham S. Long G protein-coupled cell surface receptors (GPCRs) have served a fundamental role in modern pharmacology, due to their central importance in cell communication, and have been the… Read More
The Role of Repositioning in Drug Discovery and Development By Dr Louis A. Tartaglia and Dr Lee E. Babiss The large number of drug candidate failures in recent years has been enormously costly for the pharmaceutical industry, but has also created the tremendous opportunity of repositioning these molecules into new… Read More
Implementing and Operating Large Complex Capital Projects in a Research Environment By Dr Tim Peakman UK Biobank is a major UK study that will recruit 500,000 volunteers aged between 40 and 69 to provide a resource to study the link between genetic factors, environment and lifestyle in the causes of… Read More
Innovative Partnerships in Neglected Disease Research - The Novartis Institute for Tropical Diseases By Prof Paul Herrling While the recent biomedical revolution has given rise to significant advances in medical treatment, many neglected diseases that are endemic in underdeveloped parts of the world remain unaddressed. Public-private partnerships like the Novartis… Read More
Ultra-sensitive measurement of protein and nucleic acid biomarkers may enable earlier disease detection and more effective therapies By Dr Gregory Shipp The pharmaceutical industry is striving to develop effective new therapies for diseases, ranging from cancers to cardiovascular and neurodegenerative disorders to a host of metabolic, infectious and genetic conditions,… Read More
Nanotechnology in High Throughput Screening By Dr Bobak Azamian and Flora Tang Nanotechnology has touched many scientific disciplines, from its roots in chemistry and physics to applications in biology and engineering (1). A nanotechnology industry has developed, offering at present a new iteration of established technologies such as composite materials… Read More
The Genome as a Tool for Drug Discovery and Development the Case for Embracing Complexity By Dr Kenneth C. Carter Conventional drug discovery and development is centred on a paradigm in which 'validated' targets are subjected to in vitro screens for the identification of new drug candidates. Molecular profiling using… Read More